Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure

American Heart Journal

Volumn 145, Issue 2 SUPPL., 2003, Pages

  Gheorghiade, Mihai ^a   Gattis, Wendy A ^b   Barbagelata, Alejandro ^c   Adams Jr , Kirkwood F ^d   Elkayam, Uri ^e   Orlandi, Cesare ^f   O'Connor, Christopher M ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c Inst de Cardiologia y Cirugia   (Argentina)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONIVAPTAN; PLACEBO; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; EXPERIMENTAL DESIGN; HEART STRESS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0037326532     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.154     Document Type: Conference Paper

References (10)

1. American Heart Association. 2002 Heart and stroke statistical update. Dallas: American Heart Association; 2002.
2. Cuffe MS, Califf RM, Adams KF, et al. Rationale and design of the OPTIME-CHF trial: Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbation of Chronic Heart Failure. Am Heart J 2000;139:15-22.
3. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-7.
4. Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999;100:1311-5.
5. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.
6. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-85.
7. Goldsmith SR. Vasopressin: a therapeutic target in congestive heart failure? J Cardiac Failure 1999;5:347-56.
8. 2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104:2417-23.
9. Gheorghiade M, Niazi I, Ouyang J, et al. Chronic effects of vasopressin receptor blockade with tolvaptan in congestive heart failure: a randomized double-blind trial. Circulation 2000;102:II592.
10. Gheorghiade M, Konstam MA, Udelson JE, et al. Vasopressin receptor blockade with tolvapatan in chronic heart failure: differential effects in normonatremic and hyponatremic patients. J Am Coll Cardiol 2002;39:171A.